Home » Topics » Regulatory » EMA

EMA
RSS

BioChaperone PDGF-BB to enter phase III development

March 21, 2013

Pegasys receives E.U. approval for HCV in children 5 years of age and older

March 19, 2013

Activartis gives update on its anticancer immune therapy for glioma

March 14, 2013

Roche obtains E.U. approval for Perjeta

March 6, 2013

EMA grants orphan drug status to Prothena's candidate for amyloid light-chain amyloidosis

March 5, 2013

EMA recommends approval of Sanofi Pasteur pediatric vaccine

Feb. 27, 2013

EMA confirms decision on VIVUS' MAA for obesity treatment

Feb. 25, 2013

EMA grants orphan designation to BHR Pharma's investigational agent for traumatic brain injury

Feb. 14, 2013

Prolor Biotech's hGH-CTP receives orphan drug designation in Europe

Feb. 14, 2013

Pediatric indication of Ixiaro approved in Europe

Feb. 12, 2013

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...